Lai Wei

Research Assistant Professor

Ohio State University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Lai Wei is a Research Assistant Professor at The Ohio State University, specializing in oncology and immunotherapy. His recent research focuses on the efficacy and safety of immune checkpoint inhibitors, as well as their associated toxicities and patient outcomes in various cancer types. Dr. Wei has contributed significantly to understanding the implications of imaging and medical comorbidities on cancer treatment responses.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (3)

Vineeth Sukrithan

Assistant Professor of Medicine

The Ohio State University Wexner Medical Center

UNITED STATES

View details

Gabriel Tinoco

Assistant Professor of Medicine

Ohio State University

UNITED STATES

View details

Nancy A Curtis

Ohio State University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Lai Wei

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy.

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer

Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis

Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy

Correction: Association between pre‑treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis (Cancer Immunology, Immunotherapy, (2023), 72, 6, (1727-1735), 10.1007/s00262-023-03373-y)

Improving combination therapies: targeting A<sub>2B</sub>adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression

Proton pump inhibitor therapy may alter the sensory motor characteristics of pharyngoesophageal motility in infants with suspected GERD

Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer

Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival.

Collaborators (3)

Vineeth Sukrithan

Gabriel Tinoco

Nancy A Curtis

Make your next move.